Literature DB >> 34234374

NFAT transcription factors are essential and redundant actors for leukemia initiating potential in T-cell acute lymphoblastic leukemia.

Claire Catherinet1,2,3,4, Diana Passaro1,2,3,4, Stéphanie Gachet1,2,3,4, Hind Medyouf1,2,3,4, Anne Reynaud1,2,3,4, Charlène Lasgi5, Jacques Ghysdael1,2,3,4,6, Christine Tran Quang1,2,3,4,6.   

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy with few available targeted therapies. We previously reported that the phosphatase calcineurin (Cn) is required for LIC (leukemia Initiating Capacity) potential of T-ALL pointing to Cn as an interesting therapeutic target. Calcineurin inhibitors have however unwanted side effect. NFAT transcription factors play crucial roles downstream of calcineurin during thymocyte development, T cell differentiation, activation and anergy. Here we elucidate NFAT functional relevance in T-ALL. Using murine T-ALL models in which Nfat genes can be inactivated either singly or in combination, we show that NFATs are required for T-ALL LIC potential and essential to survival, proliferation and migration of T-ALL cells. We also demonstrate that Nfat genes are functionally redundant in T-ALL and identified a node of genes commonly deregulated upon Cn or NFAT inactivation, which may serve as future candidate targets for T-ALL.

Entities:  

Year:  2021        PMID: 34234374     DOI: 10.1371/journal.pone.0254184

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  1 in total

1.  NFAM1 Promotes Pro-Inflammatory Cytokine Production in Mouse and Human Monocytes.

Authors:  Kathryn W Juchem; Anshu P Gounder; Jian Ping Gao; Elise Seccareccia; Narayana Yeddula; Nicholas J Huffmaster; Alexandra Côté-Martin; Steven E Fogal; Donald Souza; Sarah Sirui Wang; Elizabeth R A Glynn; Ivy Yung; Julie Ritchie; Li Li; Jie Zheng; M Lamine Mbow; Jun Li; Sumit K Chanda
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.